<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2015//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_150101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15033597</PMID>
        <DateCreated>
            <Year>2004</Year>
            <Month>03</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>06</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>09</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0091-6765</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>112</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2004</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Environmental health perspectives</Title>
                <ISOAbbreviation>Environ. Health Perspect.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Identification of putative gene based markers of renal toxicity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>465-79</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>This study, designed and conducted as part of the International Life Sciences Institute working group on the Application of Genomics and Proteomics, examined the changes in the expression profile of genes associated with the administration of three different nephrotoxicants--cisplatin, gentamicin, and puromycin--to assess the usefulness of microarrays in the understanding of mechanism(s) of nephrotoxicity. Male Sprague-Dawley rats were treated with daily doses of puromycin (5-20 mg/kg/day for 21 days), gentamicin (2-240 mg/kg/day for 7 days), or a single dose of cisplatin (0.1-5 mg/kg). Groups of rats were sacrificed at various times after administration of these compounds for standard clinical chemistry, urine analysis, and histological evaluation of the kidney. RNA was extracted from the kidney for microarray analysis. Principal component analysis and gene expression-based clustering of compound effects confirmed sample separation based on dose, time, and degree of renal toxicity. In addition, analysis of the profile components revealed some novel changes in the expression of genes that appeared to be associated with injury in specific portions of the nephron and reflected the mechanism of action of these various nephrotoxicants. For example, although puromycin is thought to specifically promote injury of the podocytes in the glomerulus, the changes in gene expression after chronic exposure of this compound suggested a pattern similar to the known proximal tubular nephrotoxicants cisplatin and gentamicin; this prediction was confirmed histologically. We conclude that renal gene expression profiling coupled with analysis of classical end points affords promising opportunities to reveal potential new mechanistic markers of renal toxicity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Amin</LastName>
                    <ForeName>Rupesh P</ForeName>
                    <Initials>RP</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Institute of Environmental Health Sciences, National Institutes of Health/DHHS, Research Triangle Park, North Carolina, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vickers</LastName>
                    <ForeName>Alison E</ForeName>
                    <Initials>AE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sistare</LastName>
                    <ForeName>Frank</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thompson</LastName>
                    <ForeName>Karol L</ForeName>
                    <Initials>KL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roman</LastName>
                    <ForeName>Richard J</ForeName>
                    <Initials>RJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawton</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kramer</LastName>
                    <ForeName>Jeffrey</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamadeh</LastName>
                    <ForeName>Hisham K</ForeName>
                    <Initials>HK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Collins</LastName>
                    <ForeName>Jennifer</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grissom</LastName>
                    <ForeName>Sherry</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bennett</LastName>
                    <ForeName>Lee</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tucker</LastName>
                    <ForeName>C Jeffrey</ForeName>
                    <Initials>CJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wild</LastName>
                    <ForeName>Stacie</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kind</LastName>
                    <ForeName>Clive</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oreffo</LastName>
                    <ForeName>Victor</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Davis</LastName>
                    <ForeName>John W</ForeName>
                    <Initials>JW</Initials>
                    <Suffix>2nd</Suffix>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Curtiss</LastName>
                    <ForeName>Sandra</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naciff</LastName>
                    <ForeName>Jorge M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cunningham</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tennant</LastName>
                    <ForeName>Raymond</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stevens</LastName>
                    <ForeName>James</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Car</LastName>
                    <ForeName>Bruce</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bertram</LastName>
                    <ForeName>Timothy A</ForeName>
                    <Initials>TA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Afshari</LastName>
                    <ForeName>Cynthia A</ForeName>
                    <Initials>CA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Environ Health Perspect</MedlineTA>
            <NlmUniqueID>0330411</NlmUniqueID>
            <ISSNLinking>0091-6765</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005839">Gentamicins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4A6ZS6Q2CL</RegistryNumber>
                <NameOfSubstance UI="D011691">Puromycin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q20Q21Q62J</RegistryNumber>
                <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8</RefSource>
                <PMID Version="1">9843981</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Urology. 1999 Jan;53(1):32-7</RefSource>
                <PMID Version="1">9886584</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int. 1999 Jan;55(1):100-8</RefSource>
                <PMID Version="1">9893118</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2001 Oct 5;276(40):37258-65</RefSource>
                <PMID Version="1">11486009</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int. 2002 Mar;61(3):1030-9</RefSource>
                <PMID Version="1">11849458</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 2002 Mar;22(6):1893-902</RefSource>
                <PMID Version="1">11865066</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Clin Biochem. 2002 Mar;39(Pt 2):89-104</RefSource>
                <PMID Version="1">11928770</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nephron. 2002 Apr;90(4):424-31</RefSource>
                <PMID Version="1">11961401</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int. 2002 May;61(5):1646-54</RefSource>
                <PMID Version="1">11967014</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Chem. 2002 May;48(5):699-707</RefSource>
                <PMID Version="1">11978596</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 2002 Jun;67(2):219-31</RefSource>
                <PMID Version="1">12011481</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 2002 Jun;67(2):232-40</RefSource>
                <PMID Version="1">12011482</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Mol Med. 2001 Jan-Mar;5(1):18-32</RefSource>
                <PMID Version="1">12067448</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int. 2002 Jul;62(1):237-44</RefSource>
                <PMID Version="1">12081583</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Soc Nephrol. 1999 Mar;10(3):444-57</RefSource>
                <PMID Version="1">10073594</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nephrol Dial Transplant. 1999 May;14(5):1139-45</RefSource>
                <PMID Version="1">10344352</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2004 Mar;112(4):488-94</RefSource>
                <PMID Version="1">15033599</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int. 2002 Nov;62(5):1601-10</RefSource>
                <PMID Version="1">12371960</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2002 Oct 18;277(42):39739-48</RefSource>
                <PMID Version="1">12138159</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Antioxid Redox Signal. 2002 Dec;4(6):925-34</RefSource>
                <PMID Version="1">12573141</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biomed Inform. 2002 Jun;35(3):160-70</RefSource>
                <PMID Version="1">12669979</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Renal Physiol. 2003 Jul;285(1):F9-18</RefSource>
                <PMID Version="1">12788784</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Vitam Horm. 2000;58:89-120</RefSource>
                <PMID Version="1">10668396</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Growth Horm IGF Res. 1998 Feb;8(1):77-82</RefSource>
                <PMID Version="1">10990448</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genomics. 2000 Oct 15;69(2):225-34</RefSource>
                <PMID Version="1">11031105</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochim Biophys Acta. 2000 Oct 18;1482(1-2):9-24</RefSource>
                <PMID Version="1">11058743</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Lett. 2001 Mar 31;120(1-3):359-68</RefSource>
                <PMID Version="1">11323195</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nephrol Dial Transplant. 2001 May;16(5):923-31</RefSource>
                <PMID Version="1">11328896</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Physiol Chem Phys Med NMR. 2000;32(2):119-25</RefSource>
                <PMID Version="1">11383133</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2001 Jun;17(6):564-5</RefSource>
                <PMID Version="1">11395436</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int. 2001 Aug;60(2):635-40</RefSource>
                <PMID Version="1">11473646</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2001 Aug 3;293(5531):829-34</RefSource>
                <PMID Version="1">11486081</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2001 Aug 15;175(1):28-42</RefSource>
                <PMID Version="1">11509024</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 2001 Oct;63(2):196-207</RefSource>
                <PMID Version="1">11568363</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Urol. 2002 Sep;168(3):1173-81</RefSource>
                <PMID Version="1">12187263</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Pathol. 2002 Jul-Aug;30(4):470-82</RefSource>
                <PMID Version="1">12187938</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Chem. 2002 Sep;48(9):1375-6</RefSource>
                <PMID Version="1">12194910</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Chem. 2002 Sep;48(9):1445-53</RefSource>
                <PMID Version="1">12194921</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2004 Mar;112(4):417-9</RefSource>
                <PMID Version="1">15033589</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2004 Mar;112(4):460-4</RefSource>
                <PMID Version="1">15033596</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Probl Clin Biochem. 1968;2:119-45</RefSource>
                <PMID Version="1">4359230</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1988 Sep;85(18):6768-72</RefSource>
                <PMID Version="1">3413124</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Lipid Res. 1989 Feb;30(2):171-80</RefSource>
                <PMID Version="1">2469758</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocr Rev. 1989 Nov;10(4):393-419</RefSource>
                <PMID Version="1">2693081</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int. 1990 Jun;37(6):1515-21</RefSource>
                <PMID Version="1">2362405</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1991 May 1;88(9):4020-4</RefSource>
                <PMID Version="1">1902577</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Soc Exp Biol Med. 1992 Jan;199(1):93-6</RefSource>
                <PMID Version="1">1728043</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int. 1992 Jan;41(1):226-46</RefSource>
                <PMID Version="1">1593859</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurochem. 1993 Aug;61(2):451-6</RefSource>
                <PMID Version="1">8336134</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1994 Feb 4;269(5):3698-702</RefSource>
                <PMID Version="1">8106414</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int. 1994 Mar;45(3):817-27</RefSource>
                <PMID Version="1">8196284</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Exp Nephrol. 1995 Jan-Feb;3(1):9-14</RefSource>
                <PMID Version="1">7712145</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Soc Nephrol. 1995 Oct;6(4):1186-96</RefSource>
                <PMID Version="1">8589285</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gut. 1996 Mar;38(3):414-20</RefSource>
                <PMID Version="1">8675096</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biometals. 1996 Apr;9(2):139-42</RefSource>
                <PMID Version="1">8744896</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 1996 Aug 15;318 ( Pt 1):1-14</RefSource>
                <PMID Version="1">8761444</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 1996 Dec;14(4):457-60</RefSource>
                <PMID Version="1">8944026</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Soc Nephrol. 1997 Feb;8(2):302-5</RefSource>
                <PMID Version="1">9048350</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Glycobiology. 1997 Jun;7(4):499-506</RefSource>
                <PMID Version="1">9184830</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Soc Nephrol. 1997 Sep;8(9):1383-90</RefSource>
                <PMID Version="1">9294829</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transplantation. 1997 Nov 15;64(9):1236-40</RefSource>
                <PMID Version="1">9371662</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Soc Nephrol. 1998 Jan;9(1):33-7</RefSource>
                <PMID Version="1">9440084</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1998 Feb 13;273(7):4135-42</RefSource>
                <PMID Version="1">9461608</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int Suppl. 1998 Feb;64:S19-22</RefSource>
                <PMID Version="1">9475483</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int. 1998 May;53(5):1305-13</RefSource>
                <PMID Version="1">9573546</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Reprod. 1998 Jun;58(6):1437-44</RefSource>
                <PMID Version="1">9623603</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Biotechnol. 1996 Dec;14(13):1675-80</RefSource>
                <PMID Version="1">9634850</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000900">Anti-Bacterial Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000964">Antimetabolites, Antineoplastic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002945">Cisplatin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D023381">Endpoint Determination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D020869">Gene Expression Profiling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D005819">Genetic Markers</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005839">Gentamicins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007668">Kidney</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D020411">Oligonucleotide Array Sequence Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011691">Puromycin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1241901</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>3</Month>
                <Day>23</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>6</Month>
                <Day>21</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>3</Month>
                <Day>23</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15033597</ArticleId>
            <ArticleId IdType="pmc">PMC1241901</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6316889</PMID>
        <DateCreated>
            <Year>1984</Year>
            <Month>01</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1984</Year>
            <Month>01</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0004-8291</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>13</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>1983</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Australian and New Zealand journal of medicine</Title>
                <ISOAbbreviation>Aust N Z J Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Perhexilene neuropathy: a report of two cases.</ArticleTitle>
            <Pagination>
                <MedlinePgn>517-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Two cases of sensory-motor neuropathy attributed to perhexilene maleate are described. The clinical and pathological features of perhexilene neuropathy are discussed. The use of perhexilene should be tempered with caution. Nerve conduction studies may be useful in confirming early neuropathy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lorentz</LastName>
                    <ForeName>I T</ForeName>
                    <Initials>IT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shortall</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>AUSTRALIA</Country>
            <MedlineTA>Aust N Z J Med</MedlineTA>
            <NlmUniqueID>1264322</NlmUniqueID>
            <ISSNLinking>0004-8291</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>K7V8Y90G0H</RegistryNumber>
                <NameOfSubstance UI="C023470">perhexiline maleate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>KU65374X44</RegistryNumber>
                <NameOfSubstance UI="D010480">Perhexiline</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000787">Angina Pectoris</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007866">Leg</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009431">Neural Conduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010146">Pain</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010292">Paresthesia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010480">Perhexiline</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010523">Peripheral Nervous System Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1983</Year>
                <Month>10</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1983</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1983</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6316889</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18287249</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>04</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>06</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1555-905X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>3</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical journal of the American Society of Nephrology : CJASN</Title>
                <ISOAbbreviation>Clin J Am Soc Nephrol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>747-51</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2215/CJN.05721207</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Recent studies strongly link nephrogenic systemic fibrosis to gadolinium administration for magnetic resonance imaging. In a recent advisory, the Food and Drug Administration stated that all gadolinium-containing chelates are potentially associated with nephrogenic systemic fibrosis; however, most reported cases are linked to gadodiamide (Omniscan) and gadopentetate dimeglumine (Magnevist). Given the severe consequences of nephrogenic systemic fibrosis, it is critical to define the risks associated with each gadolinium-containing chelate. The purpose of this study was to examine nephrogenic systemic fibrosis risk in a hemodialysis population exposed to gadoteridol (ProHance).</AbstractText>
                <AbstractText Label="DESIGN, SETTING, PARTICIPANTS, &amp; OBJECTIVES" NlmCategory="METHODS">Appointment logs were used to generate a database of all long-term hemodialysis patients at the Dallas Veterans Affairs hospital since August 2001. These patients were then examined in the Veterans Affair's electronic medical record system for gadolinium exposure during magnetic resonance imaging from 2000 through 2007, a period during which gadoteridol was the sole contrast agent used.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 141 patients were identified with 198 gadoteridol exposures. No cases of nephrogenic systemic fibrosis were identified. The observed frequency of nephrogenic systemic fibrosis was compared with the expected frequency (2.4%) using one-way chi(2) and binomial analysis, yielding a P &lt; 0.05, indicating that the result was not explained by chance alone.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">It is concluded that the risk for nephrogenic systemic fibrosis with gadoteridol in patients who are on long-term hemodialysis may be lower than with gadodiamide and gadopentetate dimeglumine.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Reilly</LastName>
                    <ForeName>Robert F</ForeName>
                    <Initials>RF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Nephrology, Veterans Affairs North Texas Health Care System and University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75216, USA. robert.reilly2@va.gov</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 DK079328</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 DK079328-05</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30DK079328</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>02</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin J Am Soc Nephrol</MedlineTA>
            <NlmUniqueID>101271570</NlmUniqueID>
            <ISSNLinking>1555-9041</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006571">Heterocyclic Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009942">Organometallic Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C112666">gadoversetamide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0199MV609F</RegistryNumber>
                <NameOfSubstance UI="C062402">gadoteridol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>84F6U3J2R6</RegistryNumber>
                <NameOfSubstance UI="C064925">gadodiamide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>AU0V1LM3JT</RegistryNumber>
                <NameOfSubstance UI="D005682">Gadolinium</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>K2I13DR72L</RegistryNumber>
                <NameOfSubstance UI="D019786">Gadolinium DTPA</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S192-4</RefSource>
                <PMID Version="1">12819327</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nephrol Dial Transplant. 2006 Apr;21(4):1104-8</RefSource>
                <PMID Version="1">16431890</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Soc Nephrol. 2006 Sep;17(9):2359-62</RefSource>
                <PMID Version="1">16885403</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Invest Radiol. 2007 Feb;42(2):139-45</RefSource>
                <PMID Version="1">17220732</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AJR Am J Roentgenol. 2007 Feb;188(2):586-92</RefSource>
                <PMID Version="1">17242272</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>MMWR Morb Mortal Wkly Rep. 2007 Feb 23;56(7):137-41</RefSource>
                <PMID Version="1">17318112</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiology. 2007 Apr;243(1):148-57</RefSource>
                <PMID Version="1">17267695</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AJR Am J Roentgenol. 2007 Jun;188(6):1447-74</RefSource>
                <PMID Version="1">17515363</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin J Am Soc Nephrol. 2007 Mar;2(2):264-7</RefSource>
                <PMID Version="1">17699423</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 2007 Oct;56(10):3433-41</RefSource>
                <PMID Version="1">17907148</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Radiology. 2008 Jan;246(1):11-4</RefSource>
                <PMID Version="1">17855656</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Dial. 2008 Mar-Apr;21(2):129-34</RefSource>
                <PMID Version="1">18225999</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Clin J Am Soc Nephrol. 2008 May;3(3):649-51</RefSource>
                <PMID Version="1">18385396</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003287">Contrast Media</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005355">Fibrosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005682">Gadolinium</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019786">Gadolinium DTPA</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006571">Heterocyclic Compounds</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006787">Hospitals, Veterans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007674">Kidney Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007676">Kidney Failure, Chronic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018810">Magnetic Resonance Angiography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009942">Organometallic Compounds</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D006435">Renal Dialysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018570">Risk Assessment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012871">Skin Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D013781">Texas</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC2386692</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>22</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>6</Month>
                <Day>6</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>22</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">CJN.05721207</ArticleId>
            <ArticleId IdType="doi">10.2215/CJN.05721207</ArticleId>
            <ArticleId IdType="pubmed">18287249</ArticleId>
            <ArticleId IdType="pmc">PMC2386692</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17200189</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>01</Month>
            <Day>03</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>02</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>07</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0002-9440</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>170</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The American journal of pathology</Title>
                <ISOAbbreviation>Am. J. Pathol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Asbestos-induced peribronchiolar cell proliferation and cytokine production are attenuated in lungs of protein kinase C-delta knockout mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>140-51</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The signaling pathways leading to the development of asbestos-associated diseases are poorly understood. Here we used normal and protein kinase C (PKC)-delta knockout (PKCdelta-/-) mice to demonstrate multiple roles of PKC-delta in the development of cell proliferation and inflammation after inhalation of chrysotile asbestos. At 3 days, asbestos-induced peribronchiolar cell proliferation in wild-type mice was attenuated in PKCdelta-/- mice. Cytokine profiles in bronchoalveolar lavage fluids showed increases in interleukin (IL)-1beta, IL-4, IL-6, and IL-13 that were decreased in PKCdelta-/- mice. At 9 days, microarray and quantitative reverse transcriptase-polymerase chain reaction analysis of lung tissues revealed increased mRNA levels of the profibrotic cytokine, IL-4, in asbestos-exposed wild-type mice but not PKCdelta-/- mice. PKCdelta-/- mice also exhibited decreased lung infiltration of polymorphonuclear cells, natural killer cells, and macrophages in bronchoalveolar lavage fluid and lung, as well as increased numbers of B lymphocytes and plasma cells. These changes were accompanied by elevated mRNA levels of immunoglobulin chains. These data show that modulation of PKC-delta has multiple effects on peribronchiolar cell proliferation, proinflammatory and profibrotic cytokine expression, and immune cell profiles in lung. These results also implicate targeted interruption of PKC-delta as a potential therapeutic option in asbestos-induced lung diseases.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shukla</LastName>
                    <ForeName>Arti</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, University of Vermont, 89 Beaumont Ave., Burlington, VT 05405, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lounsbury</LastName>
                    <ForeName>Karen M</ForeName>
                    <Initials>KM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barrett</LastName>
                    <ForeName>Trisha F</ForeName>
                    <Initials>TF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gell</LastName>
                    <ForeName>Joanna</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rincon</LastName>
                    <ForeName>Mercedes</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Butnor</LastName>
                    <ForeName>Kelly J</ForeName>
                    <Initials>KJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taatjes</LastName>
                    <ForeName>Douglas J</ForeName>
                    <Initials>DJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Davis</LastName>
                    <ForeName>Gerald S</ForeName>
                    <Initials>GS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vacek</LastName>
                    <ForeName>Pamela</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakayama</LastName>
                    <ForeName>Keiichi I</ForeName>
                    <Initials>KI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakayama</LastName>
                    <ForeName>Keiko</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Steele</LastName>
                    <ForeName>Chad</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mossman</LastName>
                    <ForeName>Brooke T</ForeName>
                    <Initials>BT</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P01 HL067004</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P01HL67004</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 CA022435</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30CA22435</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Pathol</MedlineTA>
            <NlmUniqueID>0370502</NlmUniqueID>
            <ISSNLinking>0002-9440</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017632">Asbestos, Serpentine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007378">Interleukins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.13</RegistryNumber>
                <NameOfSubstance UI="D051745">Protein Kinase C-delta</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.3.48</RegistryNumber>
                <NameOfSubstance UI="D017493">Antigens, CD45</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2005 Nov 1;65(21):9670-7</RefSource>
                <PMID Version="1">16266986</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Pathol. 2005 Nov;167(5):1243-56</RefSource>
                <PMID Version="1">16251409</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Leukoc Biol. 2006 Feb;79(2):408-15</RefSource>
                <PMID Version="1">16330529</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>FASEB J. 2006 May;20(7):997-9</RefSource>
                <PMID Version="1">16571779</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cytokine. 1999 Nov;11(11):839-48</RefSource>
                <PMID Version="1">10547271</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cancer Res Clin Oncol. 2000 Jan;126(1):1-11</RefSource>
                <PMID Version="1">10641743</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Cell Mol Biol. 2000 Apr;22(4):491-501</RefSource>
                <PMID Version="1">10745030</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Pathol. 2000 Apr;156(4):1307-16</RefSource>
                <PMID Version="1">10751356</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Cell Mol Biol. 2000 Aug;23(2):182-7</RefSource>
                <PMID Version="1">10919984</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunity. 2001 Jan;14(1):13-20</RefSource>
                <PMID Version="1">11163226</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2001 Nov;108(9):1395-403</RefSource>
                <PMID Version="1">11696585</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lung Cancer. 2002 Feb;35(2):171-7</RefSource>
                <PMID Version="1">11804690</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2002 Apr 25;416(6883):860-5</RefSource>
                <PMID Version="1">11976686</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2002 Apr 25;416(6883):865-9</RefSource>
                <PMID Version="1">11976687</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Pathol. 2002 Jun;160(6):1991-2000</RefSource>
                <PMID Version="1">12057904</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2002 Jul 15;166(2):236-46</RefSource>
                <PMID Version="1">12119236</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Cell Mol Biol. 2003 Apr;28(4):401-4</RefSource>
                <PMID Version="1">12654627</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2003 Jun 1;170(11):5681-9</RefSource>
                <PMID Version="1">12759450</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Cell Mol Biol. 2003 Aug;29(2):198-205</RefSource>
                <PMID Version="1">12626342</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 2003 Dec 15;376(Pt 3):545-52</RefSource>
                <PMID Version="1">14570590</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>FASEB J. 2004 Apr;18(6):627-36</RefSource>
                <PMID Version="1">15054085</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Leukoc Biol. 2004 Apr;75(4):641-8</RefSource>
                <PMID Version="1">14704366</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Indian Pediatr. 2004 Mar;41(3):292-3</RefSource>
                <PMID Version="1">15064526</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Invest Dermatol. 2004 Jun;122(6):1390-8</RefSource>
                <PMID Version="1">15175028</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2004 Jul 2;279(27):28315-9</RefSource>
                <PMID Version="1">15133032</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2004 Jul;114(1):49-56</RefSource>
                <PMID Version="1">15232611</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cytokine. 2004 Aug 21-Sep 7;27(4-5):93-100</RefSource>
                <PMID Version="1">15271374</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Cell Mol Biol. 2004 Oct;31(4):382-94</RefSource>
                <PMID Version="1">15191915</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Microbes Infect. 2004 Nov;6(13):1182-90</RefSource>
                <PMID Version="1">15488737</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Pathol Lab Med. 1982 Oct 8;106(11):544-96</RefSource>
                <PMID Version="1">6897166</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Histopathology. 1984 Nov;8(6):903-16</RefSource>
                <PMID Version="1">6098549</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1990 Jan 19;247(4940):294-301</RefSource>
                <PMID Version="1">2153315</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1990 Oct;87(19):7385-9</RefSource>
                <PMID Version="1">2170975</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Respir J. 1991 Jun;4(6):755-7</RefSource>
                <PMID Version="1">1889502</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):706-13</RefSource>
                <PMID Version="1">1892314</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Cell Mol Biol. 1993 Mar;8(3):311-8</RefSource>
                <PMID Version="1">8383510</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol. 1994 Jan;266(1 Pt 1):L84-91</RefSource>
                <PMID Version="1">8304471</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 1996 Mar;137(1):67-74</RefSource>
                <PMID Version="1">8607143</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Cell Mol Biol. 1996 Dec;15(6):693-702</RefSource>
                <PMID Version="1">8969262</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Cell Mol Biol. 1997 Jan;16(1):91-101</RefSource>
                <PMID Version="1">8998084</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 1997 Nov;147(1):143-50</RefSource>
                <PMID Version="1">9356317</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1666-80</RefSource>
                <PMID Version="1">9603153</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 1998 Jun 1;332 ( Pt 2):281-92</RefSource>
                <PMID Version="1">9601053</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Pathol. 2005 Nov;167(5):1231-41</RefSource>
                <PMID Version="1">16251408</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2006 Jan;116(1):163-73</RefSource>
                <PMID Version="1">16374521</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017493">Antigens, CD45</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017632">Asbestos, Serpentine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015971">Gene Expression Regulation, Enzymologic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007378">Interleukins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007694">Killer Cells, Natural</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008171">Lung Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016131">Lymphocyte Subsets</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051745">Protein Kinase C-delta</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011658">Pulmonary Fibrosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1762688</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>1</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>2</Month>
                <Day>22</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>1</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0002-9440(10)60841-3</ArticleId>
            <ArticleId IdType="doi">10.2353/ajpath.2007.060381</ArticleId>
            <ArticleId IdType="pubmed">17200189</ArticleId>
            <ArticleId IdType="pmc">PMC1762688</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12559675</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>01</Month>
            <Day>31</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>07</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0895-7061</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>16</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of hypertension</Title>
                <ISOAbbreviation>Am. J. Hypertens.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A new model of isolated systolic hypertension induced by chronic warfarin and vitamin K1 treatment.</ArticleTitle>
            <Pagination>
                <MedlinePgn>103-10</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Isolated systolic hypertension is the predominant form of hypertension in the elderly population. Reduction of arterial compliance appears to contribute to the elevation of pulse pressure (PP) and among potential mechanisms, gradual vascular calcification, fragmentation of elastic lamellae, and augmentation of rigid component like collagen could contribute to increase aortic stiffening. Few experimental models of the disease are currently available.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">To induce large artery calcification, rats were treated with warfarin and vitamin K(1) (WK) for 4 and 8 weeks, to inhibit the maturation of matrix Gla protein. The impact of chronic PP elevation was determined on large artery and cardiac remodeling and on aortic endothelial function.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The WK treatment led to aortic medial calcification and a proportional elevation of PP, attributable mainly to a selective elevation of systolic blood pressure. The chronic treatment also increased collagen, whereas elastin decreased in the aorta. Pulse wave velocity, an index of aortic stiffening, increased in rats treated with WK. However, indices of left ventricular and aortic hypertrophy and remodeling remained normal. In addition, the WK treatment did not modify the vasoconstriction to norepinephrine and endothelin-1, and the vasodilatory response to acetylcholine and sodium nitroprusside.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Chronic treatment with WK represents a new model of isolated systolic hypertension with several characteristics of the human disease. The relative ease to induce calcification in this model may help to foster more fundamental research, which is lacking in this type of hypertension.</AbstractText>
                <CopyrightInformation>Copyright 2003 American Journal of Hypertension, Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Essalihi</LastName>
                    <ForeName>Rachida</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Pharmacy, Universit de Montral, Montral, Qubec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dao</LastName>
                    <ForeName>Huy Hao</ForeName>
                    <Initials>HH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamaguchi</LastName>
                    <ForeName>Nobuharu</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moreau</LastName>
                    <ForeName>Pierre</ForeName>
                    <Initials>P</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Hypertens</MedlineTA>
            <NlmUniqueID>8803676</NlmUniqueID>
            <ISSNLinking>0895-7061</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5Q7ZVV76EI</RegistryNumber>
                <NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>84-80-0</RegistryNumber>
                <NameOfSubstance UI="D010837">Vitamin K 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9007-34-5</RegistryNumber>
                <NameOfSubstance UI="D003094">Collagen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9007-58-3</RegistryNumber>
                <NameOfSubstance UI="D004549">Elastin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.23.15</RegistryNumber>
                <NameOfSubstance UI="D012083">Renin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>SY7Q814VUP</RegistryNumber>
                <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000925">Anticoagulants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000933">Antifibrinolytic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001011">Aorta</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002114">Calcinosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002118">Calcium</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003094">Collagen</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004549">Elastin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006439">Hemodynamics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012083">Renin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013599">Systole</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014652">Vascular Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014666">Vasomotor System</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010837">Vitamin K 1</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014859">Warfarin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>7</Month>
                <Day>23</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12559675</ArticleId>
            <ArticleId IdType="pii">S0895706102032041</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">5414890</PMID>
        <DateCreated>
            <Year>1970</Year>
            <Month>04</Month>
            <Day>02</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1970</Year>
            <Month>04</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-987X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>101</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1970</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Archives of dermatology</Title>
                <ISOAbbreviation>Arch Dermatol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Skin temperature changes in Raynaud's disease after griseofulvin.</ArticleTitle>
            <Pagination>
                <MedlinePgn>331-6</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Charles</LastName>
                    <ForeName>C R</ForeName>
                    <Initials>CR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carmick</LastName>
                    <ForeName>E S</ForeName>
                    <Initials>ES</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Arch Dermatol</MedlineTA>
            <NlmUniqueID>0372433</NlmUniqueID>
            <ISSNLinking>0003-987X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>32HRV3E3D5</RegistryNumber>
                <NameOfSubstance UI="D006118">Griseofulvin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001833">Body Temperature Regulation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006118">Griseofulvin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011928">Raynaud Disease</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012881">Skin Temperature</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1970</Year>
                <Month>3</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1970</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1970</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">5414890</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10809044</PMID>
        <DateCreated>
            <Year>2000</Year>
            <Month>05</Month>
            <Day>30</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2000</Year>
            <Month>05</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-9926</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>160</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2000</Year>
                        <Month>May</Month>
                        <Day>8</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Archives of internal medicine</Title>
                <ISOAbbreviation>Arch. Intern. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hallucinations in an elderly patient taking recommended doses of cyclobenzaprine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1373</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Douglass</LastName>
                    <ForeName>M A</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Levine</LastName>
                    <ForeName>D P</ForeName>
                    <Initials>DP</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Arch Intern Med</MedlineTA>
            <NlmUniqueID>0372440</NlmUniqueID>
            <ISSNLinking>0003-9926</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009125">Muscle Relaxants, Central</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1806D8D52K</RegistryNumber>
                <NameOfSubstance UI="D000639">Amitriptyline</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>69O5WQQ5TI</RegistryNumber>
                <NameOfSubstance UI="C004704">cyclobenzaprine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000639">Amitriptyline</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004347">Drug Interactions</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006212">Hallucinations</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009125">Muscle Relaxants, Central</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2000</Year>
                <Month>5</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2000</Year>
                <Month>6</Month>
                <Day>3</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2000</Year>
                <Month>5</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10809044</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">14738236</PMID>
        <DateCreated>
            <Year>2004</Year>
            <Month>01</Month>
            <Day>23</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>04</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>05</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0903-1936</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>23</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2004</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The European respiratory journal</Title>
                <ISOAbbreviation>Eur. Respir. J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Different airway inflammatory responses in asthmatic and healthy humans exposed to diesel.</ArticleTitle>
            <Pagination>
                <MedlinePgn>82-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Particulate matter (PM) pollution adversely affects the airways, with asthmatic subjects thought to be especially sensitive. The authors hypothesised that exposure to diesel exhaust (DE), a major source of PM, would induce airway neutrophilia in healthy subjects, and that either these responses would be exaggerated in subjects with mild allergic asthma, or DE would exacerbate pre-existent allergic airways. Healthy and mild asthmatic subjects were exposed for 2 h to ambient levels of DE (particles with a 50% cut-off aerodynamic diameter of 10 microm (PM10) 108 microg x m(-3)) and lung function and airway inflammation were assessed. Both groups showed an increase in airway resistance of similar magnitude after DE exposure. Healthy subjects developed airway inflammation 6 h after DE exposure, with airways neutrophilia and lymphocytosis together with an increase in interleukin-8 (IL-8) protein in lavage fluid, increased IL-8 messenger ribonucleic acid expression in the bronchial mucosa and upregulation of the endothelial adhesion molecules. In asthmatic subjects, DE exposure did not induce a neutrophilic response or exacerbate their pre-existing eosinophilic airway inflammation. Epithelial staining for the cytokine IL-10 was increased after DE in the asthmatic group. Differential effects on the airways of healthy subjects and asthmatics of particles with a 50% cut-off aerodynamic diameter of 10 microm at concentrations below current World Health Organisation air quality standards have been observed in this study. Further work is required to elucidate the significance of these differential responses.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Stenfors</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dept of Respiratory Medicine and Allergy, University Hospital, Ume, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nordenhll</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salvi</LastName>
                    <ForeName>S S</ForeName>
                    <Initials>SS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mudway</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sderberg</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blomberg</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Helleday</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Levin</LastName>
                    <ForeName>J O</ForeName>
                    <Initials>JO</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Holgate</LastName>
                    <ForeName>S T</ForeName>
                    <Initials>ST</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kelly</LastName>
                    <ForeName>F J</ForeName>
                    <Initials>FJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Frew</LastName>
                    <ForeName>A J</ForeName>
                    <Initials>AJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sandstrm</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Denmark</Country>
            <MedlineTA>Eur Respir J</MedlineTA>
            <NlmUniqueID>8803460</NlmUniqueID>
            <ISSNLinking>0903-1936</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015815">Cell Adhesion Molecules</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001335">Vehicle Emissions</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>130068-27-8</RegistryNumber>
                <NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000403">Airway Resistance</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001249">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001980">Bronchi</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001992">Bronchoalveolar Lavage Fluid</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015815">Cell Adhesion Molecules</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004781">Environmental Exposure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007249">Inflammation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016753">Interleukin-10</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016209">Interleukin-8</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008218">Lymphocytosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009504">Neutrophils</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020545">Respiratory Mucosa</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012137">Respiratory System</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001335">Vehicle Emissions</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>1</Month>
                <Day>24</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>4</Month>
                <Day>28</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>1</Month>
                <Day>24</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14738236</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17263743</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>01</Month>
            <Day>31</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>04</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1155-5645</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>17</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Paediatric anaesthesia</Title>
                <ISOAbbreviation>Paediatr Anaesth</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>270-2</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure. We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump. Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety. During induction of anesthesia, the patient developed bradycardia and hypotension requiring cardiac resuscitation. There are no previous reports of clonidine-associated cardiac arrest in a child undergoing induction of anesthesia.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Goldfinger</LastName>
                    <ForeName>Mark M</ForeName>
                    <Initials>MM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pediatric Anesthesiology, Rainbow Babies and Children's Hospital, Case Western Reserve University, Cleveland, Ohio, USA. mark.goldfinger@uhhs.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tripi</LastName>
                    <ForeName>Paul A</ForeName>
                    <Initials>PA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>Paediatr Anaesth</MedlineTA>
            <NlmUniqueID>9206575</NlmUniqueID>
            <ISSNLinking>1155-5645</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000316">Adrenergic alpha-Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018685">Anesthetics, Inhalation</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008738">Methyl Ethers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>38LVP0K73A</RegistryNumber>
                <NameOfSubstance UI="C009250">sevoflurane</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>MN3L5RMN02</RegistryNumber>
                <NameOfSubstance UI="D003000">Clonidine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000316">Adrenergic alpha-Agonists</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000768">Anesthesia, General</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018685">Anesthetics, Inhalation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002547">Cerebral Palsy</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003000">Clonidine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006323">Heart Arrest</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008738">Methyl Ethers</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011229">Preanesthetic Medication</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>4</Month>
                <Day>17</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">PAN2065</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1460-9592.2006.02065.x</ArticleId>
            <ArticleId IdType="pubmed">17263743</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10809043</PMID>
        <DateCreated>
            <Year>2000</Year>
            <Month>05</Month>
            <Day>30</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2000</Year>
            <Month>05</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-9926</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>160</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2000</Year>
                        <Month>May</Month>
                        <Day>8</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Archives of internal medicine</Title>
                <ISOAbbreviation>Arch. Intern. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hemolytic uremic syndrome associated with clopidogrel: a case report.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1370-2</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Clopidogrel and ticlopidine are antiplatelet agents used in the treatment of patients with cerebrovascular and peripheral vascular disease and to reduce the risk for thrombosis in patients undergoing coronary artery stenting. Ticlopidine has been reported to have major hematologic adverse effects, including neutropenia and thrombotic thrombocytopenic purpura or hemolytic uremic syndrome (HUS). Clopidogrel, an analogue of ticlopidine, was developed because it did not show bone marrow toxic effects in either tissue culture or animal models. In human studies, to date, clopidogrel has been associated with a low incidence of severe neutropenia and no reported cases of thrombotic thrombocytopenic purpura or HUS. For these reasons, clopidogrel has been increasingly used in place of ticlopidine after coronary artery stenting. We report a case of clopidogrel-associated HUS. This observation implicates clopidogrel as a possible causative agent in HUS.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Moy</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>J C</ForeName>
                    <Initials>JC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Raffel</LastName>
                    <ForeName>G D</ForeName>
                    <Initials>GD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marcoux</LastName>
                    <ForeName>J P</ForeName>
                    <Initials>JP</Initials>
                    <Suffix>2nd</Suffix>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Arch Intern Med</MedlineTA>
            <NlmUniqueID>0372440</NlmUniqueID>
            <ISSNLinking>0003-9926</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>A74586SNO7</RegistryNumber>
                <NameOfSubstance UI="C055162">clopidogrel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>OM90ZUW7M1</RegistryNumber>
                <NameOfSubstance UI="D013988">Ticlopidine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000789">Angina, Unstable</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006463">Hemolytic-Uremic Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010956">Plasmapheresis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010975">Platelet Aggregation Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015607">Stents</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013988">Ticlopidine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2000</Year>
                <Month>5</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2000</Year>
                <Month>6</Month>
                <Day>3</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2000</Year>
                <Month>5</Month>
                <Day>16</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10809043</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">14968361</PMID>
        <DateCreated>
            <Year>2004</Year>
            <Month>03</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>08</Month>
            <Day>31</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0340-6199</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>163</Volume>
                    <Issue>4-5</Issue>
                    <PubDate>
                        <Year>2004</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of pediatrics</Title>
                <ISOAbbreviation>Eur. J. Pediatr.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Maternal administration of high dose vitamin D3 for cerebral palsy in her child.</ArticleTitle>
            <Pagination>
                <MedlinePgn>279-80</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zimmermann</LastName>
                    <ForeName>Bettina</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Paediatrics, University of Erlangen-Nrnberg, Loschgestrasse 15, 91054 Erlangen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Drr</LastName>
                    <ForeName>Helmuth-Gnther</ForeName>
                    <Initials>HG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mller</LastName>
                    <ForeName>Wolfgang</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dtsch</LastName>
                    <ForeName>Jrg</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2004</Year>
                <Month>02</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Eur J Pediatr</MedlineTA>
            <NlmUniqueID>7603873</NlmUniqueID>
            <ISSNLinking>0340-6199</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>1C6V77QF41</RegistryNumber>
                <NameOfSubstance UI="D002762">Cholecalciferol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002547">Cerebral Palsy</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002762">Cholecalciferol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006130">Growth Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006934">Hypercalcemia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009123">Muscle Hypotonia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D011297">Prenatal Exposure Delayed Effects</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>2</Month>
                <Day>18</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2003</Year>
                <Month>Oct</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2004</Year>
                <Month>Jan</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2004</Year>
                <Month>Feb</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>2</Month>
                <Day>18</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14968361</ArticleId>
            <ArticleId IdType="doi">10.1007/s00431-004-1414-0</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3015567</PMID>
        <DateCreated>
            <Year>1986</Year>
            <Month>09</Month>
            <Day>19</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1986</Year>
            <Month>09</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0013-7227</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>119</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1986</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Endocrinology</Title>
                <ISOAbbreviation>Endocrinology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inhibition of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation by delayed glucocorticoid feedback.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1126-30</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Nitroprusside-induced hypotension evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor (irCRF) into the hypophysial-portal circulation. Portal plasma concentrations of neither arginine vasopressin nor oxytocin are significantly altered in this paradigm. Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested. Resting irCRF levels are suppressed only at the highest corticosterone infusion rate, which resulted in systemic corticosterone levels of 40 micrograms/dl. Suppression of irCRF secretion in response to nitroprusside-induced hypotension is observed and occurs at a plasma corticosterone level between 8-12 micrograms/dl. These studies provide further evidence for a strong central component of the delayed feedback process which is mediated by modulation of irCRF release.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Plotsky</LastName>
                    <ForeName>P M</ForeName>
                    <Initials>PM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Otto</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sapolsky</LastName>
                    <ForeName>R M</ForeName>
                    <Initials>RM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>AM-33093</GrantID>
                    <Acronym>AM</Acronym>
                    <Agency>NIADDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Endocrinology</MedlineTA>
            <NlmUniqueID>0375040</NlmUniqueID>
            <ISSNLinking>0013-7227</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>113-79-1</RegistryNumber>
                <NameOfSubstance UI="D001127">Arginine Vasopressin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>169D1260KM</RegistryNumber>
                <NameOfSubstance UI="D009599">Nitroprusside</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>50-56-6</RegistryNumber>
                <NameOfSubstance UI="D010121">Oxytocin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9002-60-2</RegistryNumber>
                <NameOfSubstance UI="D000324">Adrenocorticotropic Hormone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9015-71-8</RegistryNumber>
                <NameOfSubstance UI="D003346">Corticotropin-Releasing Hormone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>W980KJ009P</RegistryNumber>
                <NameOfSubstance UI="D003345">Corticosterone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000324">Adrenocorticotropic Hormone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001127">Arginine Vasopressin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003345">Corticosterone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003346">Corticotropin-Releasing Hormone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005856">Germ-Free Life</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005938">Glucocorticoids</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007022">Hypotension</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009599">Nitroprusside</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010121">Oxytocin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010902">Pituitary Gland</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000098">blood supply</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011169">Portal Vein</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011919">Rats, Inbred Strains</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1986</Year>
                <Month>9</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1986</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1986</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3015567</ArticleId>
            <ArticleId IdType="doi">10.1210/endo-119-3-1126</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9284429</PMID>
        <DateCreated>
            <Year>1997</Year>
            <Month>12</Month>
            <Day>03</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1997</Year>
            <Month>12</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0047-1852</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>55</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>1997</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nihon rinsho. Japanese journal of clinical medicine</Title>
                <ISOAbbreviation>Nippon Rinsho</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Treatment of hypertension associated with diabetes mellitus].</ArticleTitle>
            <Pagination>
                <MedlinePgn>2091-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The number of patients with non-insulin-dependent-diabetes mellitus (NIDDM) is dramatically increasing in Japan and estimated to be 6 million, more than one of ten adults. It is well known that more than a half of diabetics are hypertensive. Therefore, it is very important to treat hypertension to reduce cardiovascular events as well as end-stage renal disease. At first, life style modification such as body weight reduction, exercise and restriction of salt and alcohol intake will be recommended. Improved glycemic control by such a non-pharmacological therapy will lower blood pressure. Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and troglitazone reduce blood pressure. If these maneuvers do not lower blood pressure, hypotensive medication will be necessary. As a first line therapy, ACE inhibitor, alpha 1-blocker or Ca-channel blocker will be selected. In diabetics with proteinuria or micro-albuminuria, ACE inhibitors will be effective to delay the progression of diabetic nephropathy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Katayama</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fourth Department of Medicine, Saitama Medical School.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>jpn</Language>
            <PublicationTypeList>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>JAPAN</Country>
            <MedlineTA>Nihon Rinsho</MedlineTA>
            <NlmUniqueID>0420546</NlmUniqueID>
            <ISSNLinking>0047-1852</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002839">Chromans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D045162">Thiazolidinediones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9100L32L2N</RegistryNumber>
                <NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I66ZZ0ZN0E</RegistryNumber>
                <NameOfSubstance UI="C057693">troglitazone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000806">Angiotensin-Converting Enzyme Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D000959">Antihypertensive Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002561">Cerebrovascular Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002839">Chromans</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003327">Coronary Disease</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003924">Diabetes Mellitus, Type 2</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003925">Diabetic Angiopathies</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003928">Diabetic Nephropathies</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006949">Hyperlipidemias</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007004">Hypoglycemic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007333">Insulin Resistance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008687">Metformin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009765">Obesity</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013844">Thiazoles</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D045162">Thiazolidinediones</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>10</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1997</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1997</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1997</Year>
                <Month>8</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9284429</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15812121</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>04</Month>
            <Day>06</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>04</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">0973-7693</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>72</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Indian journal of pediatrics</Title>
                <ISOAbbreviation>Indian J Pediatr</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sodium valproate -- induced skeletal myopathy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>243-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The authors report a case of skeletal myopathy in a four-year-old boy on long-term sodium valproate therapy for secondary epilepsy due to neurocysticercosis. He presented with clinical features of limb girdle weakness. EMG revealed features of myopathy. Carnitine deficiency due to sodium valproate was suspected and plasma carnitine levels were found to be low. Sodium valproate was withdrawn. L-carnitine supplementation resulted in marked clinical recovery as well as rise in plasma carnitine levels.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kasturi</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Bhabha Atomic Research Centre Hospital, Anushaktinagar, Mumbai, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sawant</LastName>
                    <ForeName>Sangeeta P</ForeName>
                    <Initials>SP</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>India</Country>
            <MedlineTA>Indian J Pediatr</MedlineTA>
            <NlmUniqueID>0417442</NlmUniqueID>
            <ISSNLinking>0019-5456</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>33CM23913M</RegistryNumber>
                <NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>541-15-1</RegistryNumber>
                <NameOfSubstance UI="D002331">Carnitine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>614OI1Z5WI</RegistryNumber>
                <NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002220">Carbamazepine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002331">Carnitine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000172">deficiency</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004827">Epilepsy</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009135">Muscular Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014635">Valproic Acid</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014804">Vitamin B Deficiency</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>4</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>4</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>4</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15812121</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">5953529</PMID>
        <DateCreated>
            <Year>1967</Year>
            <Month>01</Month>
            <Day>30</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1967</Year>
            <Month>01</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>17</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0098-7484</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>198</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>1966</Year>
                        <Month>Dec</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>JAMA</Title>
                <ISOAbbreviation>JAMA</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Penicillamine and the nephrotic syndrome.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1311-2</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sternlieb</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>JAMA</MedlineTA>
            <NlmUniqueID>7501160</NlmUniqueID>
            <ISSNLinking>0098-7484</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>GNN1DV99GX</RegistryNumber>
                <NameOfSubstance UI="D010396">Penicillamine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006527">Hepatolenticular Degeneration</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009404">Nephrotic Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010396">Penicillamine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1966</Year>
                <Month>12</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1966</Year>
                <Month>12</Month>
                <Day>19</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1966</Year>
                <Month>12</Month>
                <Day>19</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">5953529</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19853593</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>12</Month>
            <Day>16</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>01</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7786</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>183</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Jan</Month>
                        <Day>5</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Chemico-biological interactions</Title>
                <ISOAbbreviation>Chem. Biol. Interact.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Protective effect of anacardic acids from cashew (Anacardium occidentale) on ethanol-induced gastric damage in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>264-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cbi.2009.10.008</ELocationID>
            <Abstract>
                <AbstractText>Cashew nut-shell liquid and the contained anacardic acids (AAs) have been shown to possess antioxidant, lipoxygenase inhibitory, anti-Helicobacter pylori and antitumor properties. Despite these known effects, hitherto there were no published reports on their likely gastroprotective effects. The present study was designed to verify whether AAs afford gastroprotection against the ethanol-induced gastric damage and to examine the underlying mechanism(s). Gastric damage was induced by intragastric administration of 0.2mL of ethanol (96%). Mice in groups were pretreated orally with AAs (10, 30 and 100mg/kg), misoprostol (50 microg/kg), or vehicle (2% Tween 80 in saline, 10mL/kg), 45min before ethanol administration. They were sacrificed 30min later, the stomachs excised, and the mucosal lesion area (mm(2)) measured by planimetry. Gastroprotection was assessed in relation to inhibition of gastric lesion area. To study the gastroprotective mechanism(s), its relations to capsaicin-sensitive fibers, endogenous prostaglandins, nitric oxide and ATP-sensitive potassium channels were analysed. Treatments effects on ethanol-associated oxidative stress markers GSH, MDA, catalase, SOD, and total nitrate/nitrite levels as an index of NO were measured in gastric tissue. Besides, the effects of AAs on gastric secretory volume and total acidity were analysed in 4-h pylorus-ligated rat. AAs afforded a dose-related gastroprotection against the ethanol damage and further prevented the ethanol-induced changes in the levels of GSH, MDA, catalase, SOD and nitrate/nitrite. However, they failed to modify the gastric secretion or the total acidity. It was observed that the gastroprotection by AAs was greatly reduced in animals pretreated with capsazepine, indomethacin, l-NAME or glibenclamide. These results suggest that AAs afford gastroprotection principally through an antioxidant mechanism. Other complementary mechanisms include the activation of capsaicin-sensitive gastric afferents, stimulation of endogenous prostaglandins and nitric oxide, and opening of K(+)(ATP) channels. These combined effects are likely to be accompanied by an increase in gastric microcirculation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Morais</LastName>
                    <ForeName>Talita C</ForeName>
                    <Initials>TC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Physiology and Pharmacology, Biomedical Institute of Brazilian Semi-arid, Faculty of Medicine, Federal University of Cear, Fortaleza, CE, Brazil.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pinto</LastName>
                    <ForeName>Natlia B</ForeName>
                    <Initials>NB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carvalho</LastName>
                    <ForeName>Karine Maria M B</ForeName>
                    <Initials>KM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rios</LastName>
                    <ForeName>Jeison B</ForeName>
                    <Initials>JB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ricardo</LastName>
                    <ForeName>Nagila Maria P S</ForeName>
                    <Initials>NM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trevisan</LastName>
                    <ForeName>Maria Teresa S</ForeName>
                    <Initials>MT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rao</LastName>
                    <ForeName>Vietla S</ForeName>
                    <Initials>VS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santos</LastName>
                    <ForeName>Flvia A</ForeName>
                    <Initials>FA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Chem Biol Interact</MedlineTA>
            <NlmUniqueID>0227276</NlmUniqueID>
            <ISSNLinking>0009-2797</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D048729">Anacardic Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000897">Anti-Ulcer Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D054086">KATP Channels</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011453">Prostaglandins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>31C4KY9ESH</RegistryNumber>
                <NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3K9958V90M</RegistryNumber>
                <NameOfSubstance UI="D000431">Ethanol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4Y8F71G49Q</RegistryNumber>
                <NameOfSubstance UI="D008315">Malondialdehyde</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.11.1.6</RegistryNumber>
                <NameOfSubstance UI="D002374">Catalase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.15.1.1</RegistryNumber>
                <NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>LFW48MY844</RegistryNumber>
                <NameOfSubstance UI="C071423">capsazepine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>S07O44R1ZM</RegistryNumber>
                <NameOfSubstance UI="D002211">Capsaicin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D048729">Anacardic Acids</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D031021">Anacardium</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000897">Anti-Ulcer Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000975">Antioxidants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002211">Capsaicin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002374">Catalase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000431">Ethanol</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005753">Gastric Mucosa</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D054086">KATP Channels</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008315">Malondialdehyde</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009569">Nitric Oxide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011453">Prostaglandins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013276">Stomach Ulcer</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013482">Superoxide Dismutase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>1</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0009-2797(09)00437-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cbi.2009.10.008</ArticleId>
            <ArticleId IdType="pubmed">19853593</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15802798</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>04</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>08</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0918-6158</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>28</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biological &amp; pharmaceutical bulletin</Title>
                <ISOAbbreviation>Biol. Pharm. Bull.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inhibition of hepatocyte growth factor production in human fibroblasts by ursodeoxycholic acid.</ArticleTitle>
            <Pagination>
                <MedlinePgn>619-24</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Hepatocyte growth factor (HGF) stimulates the proliferation of hepatocytes and biliary epithelial cells and protects hepatocytes from apoptosis induced by various stimuli. In view of HGF induction by interferons, substances used for the treatment of chronic hepatitis C, this study was conducted to determine whether ursodeoxycholic acid (UDCA), which is widely used for the treatment of cholestatic liver diseases, modulates HGF production. UDCA did not induce HGF production in human dermal fibroblasts, but it potently inhibited phorbol-12-myristate-13-acetate (PMA)- and cholera-toxin-induced HGF production without affecting cell viability. The inhibitory effects of UDCA were as potent as those of transforming growth factor-beta1 and dexamethasone. Up-regulations of HGF gene expression induced by PMA and cholera toxin were also inhibited by UDCA. Moreover, UDCA dose-dependently inhibited high constitutive HGF production by MRC-5 cells without decreasing cell viability. Deoxycholate, chenodeoxycholate, taurochenodeoxycholate and glycochenodeoxycholate also inhibited cholera-toxin-induced HGF production at non-cytotoxic doses. UDCA, however, had no apparent effect on PMA-induced phosphorylation of mitogen-activated protein kinase, which is crucial for HGF induction by PMA. These results indicate that non-cytotoxic doses of UDCA inhibited constitutive and induced HGF production and suggest that UDCA supplemented with HGF or HGF inducers could have a more potential therapeutic effect.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hiramatsu</LastName>
                    <ForeName>Kaori</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Immunochemistry, Faculty of Pharmaceutical Sciences, Okayama University, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsumoto</LastName>
                    <ForeName>Yohsuke</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miyazaki</LastName>
                    <ForeName>Masahiro</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsubouchi</LastName>
                    <ForeName>Hirohito</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamamoto</LastName>
                    <ForeName>Itaru</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gohda</LastName>
                    <ForeName>Eiichi</ForeName>
                    <Initials>E</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>Biol Pharm Bull</MedlineTA>
            <NlmUniqueID>9311984</NlmUniqueID>
            <ISSNLinking>0918-6158</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>67256-21-7</RegistryNumber>
                <NameOfSubstance UI="D017228">Hepatocyte Growth Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>724L30Y2QR</RegistryNumber>
                <NameOfSubstance UI="D014580">Ursodeoxycholic Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9012-63-9</RegistryNumber>
                <NameOfSubstance UI="D002772">Cholera Toxin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.24</RegistryNumber>
                <NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>NI40JAQ945</RegistryNumber>
                <NameOfSubstance UI="D013755">Tetradecanoylphorbol Acetate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002772">Cholera Toxin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015536">Down-Regulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005347">Fibroblasts</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017228">Hepatocyte Growth Factor</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020928">Mitogen-Activated Protein Kinases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013755">Tetradecanoylphorbol Acetate</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014580">Ursodeoxycholic Acid</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>4</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>4</Month>
                <Day>2</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">JST.JSTAGE/bpb/28.619</ArticleId>
            <ArticleId IdType="pubmed">15802798</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">21239484</PMID>
        <DateCreated>
            <Year>2011</Year>
            <Month>03</Month>
            <Day>30</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2011</Year>
            <Month>05</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1083-351X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>286</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Mar</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of biological chemistry</Title>
                <ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Arginine deficiency causes runting in the suckling period by selectively activating the stress kinase GCN2.</ArticleTitle>
            <Pagination>
                <MedlinePgn>8866-74</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M110.216119</ELocationID>
            <Abstract>
                <AbstractText>Suckling &quot;F/A2&quot; mice, which overexpress arginase-I in their enterocytes, develop a syndrome (hypoargininemia, reduced hair and muscle growth, impaired B-cell maturation) that resembles IGF1 deficiency. The syndrome may result from an impaired function of the GH-IGF1 axis, activation of the stress-kinase GCN2, and/or blocking of the mTORC1-signaling pathway. Arginine deficiency inhibited GH secretion and decreased liver Igf1 mRNA and plasma IGF1 concentration, but did not change muscle IGF1 concentration. GH supplementation induced Igf1 mRNA synthesis, but did not restore growth, ruling out direct involvement of the GH-IGF1 axis. In C2C12 muscle cells, arginine withdrawal activated GCN2 signaling, without impacting mTORC1 signaling. In F/A2 mice, the reduction of plasma and tissue arginine concentrations to 25% of wild-type values activated GCN2 signaling, but mTORC1-mediated signaling remained unaffected. Gcn2-deficient F/A2 mice suffered from hypoglycemia and died shortly after birth. Because common targets of all stress kinases (eIF2 phosphorylation, Chop mRNA expression) were not increased in these mice, the effects of arginine deficiency were solely mediated by GCN2.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Marion</LastName>
                    <ForeName>Vincent</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dept of Anatomy &amp; Embryology and NUTRIM School for Nutrition, Toxicology, and Metabolism, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sankaranarayanan</LastName>
                    <ForeName>Selvakumari</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Theije</LastName>
                    <ForeName>Chiel</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Dijk</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lindsey</LastName>
                    <ForeName>Patrick</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lamers</LastName>
                    <ForeName>Marinus C</ForeName>
                    <Initials>MC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harding</LastName>
                    <ForeName>Heather P</ForeName>
                    <Initials>HP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ron</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lamers</LastName>
                    <ForeName>Wouter H</ForeName>
                    <Initials>WH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Khler</LastName>
                    <ForeName>S Eleonore</ForeName>
                    <Initials>SE</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>084812</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2011</Year>
                <Month>01</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Biol Chem</MedlineTA>
            <NlmUniqueID>2985121R</NlmUniqueID>
            <ISSNLinking>0021-9258</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C519530">insulin-like growth factor-1, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C576553">mechanistic target of rapamycin complex 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>67763-96-6</RegistryNumber>
                <NameOfSubstance UI="D007334">Insulin-Like Growth Factor I</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9002-72-6</RegistryNumber>
                <NameOfSubstance UI="D013006">Growth Hormone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>94ZLA3W45F</RegistryNumber>
                <NameOfSubstance UI="D001120">Arginine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.1</RegistryNumber>
                <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="C070634">Eif2ak4 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.5.3.1</RegistryNumber>
                <NameOfSubstance UI="C544448">Arg1 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.5.3.1</RegistryNumber>
                <NameOfSubstance UI="D001119">Arginase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 1998 Nov 15;336 ( Pt 1):1-17</RefSource>
                <PMID Version="1">9806879</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7324-9</RefSource>
                <PMID Version="1">10377413</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2005 Jan 7;326(1):174-80</RefSource>
                <PMID Version="1">15567168</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 2005 Apr;146(4):1772-9</RefSource>
                <PMID Version="1">15618350</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Sci. 2005 Mar;97(3):408-16</RefSource>
                <PMID Version="1">15750284</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Nutr. 2005 Feb;93(2):183-9</RefSource>
                <PMID Version="1">15788111</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Mol Cell Biol. 2005 Apr;6(4):318-27</RefSource>
                <PMID Version="1">15803138</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Sheng Li Xue Bao. 2005 Apr 25;57(2):254-8</RefSource>
                <PMID Version="1">15830113</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Soc Trans. 2006 Feb;34(Pt 1):7-11</RefSource>
                <PMID Version="1">16246168</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Invest Dermatol. 2005 Nov;125(5):873-82</RefSource>
                <PMID Version="1">16297183</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Retrovirology. 2006;3:2</RefSource>
                <PMID Version="1">16398936</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Cell Biol. 2006 Apr;84(2):215-31</RefSource>
                <PMID Version="1">16609703</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Sci. 2006 Oct;102(2):147-54</RefSource>
                <PMID Version="1">17031076</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2007 Apr 20;129(2):434</RefSource>
                <PMID Version="1">17449000</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Genet. 2007 Aug;122(1):1-21</RefSource>
                <PMID Version="1">17534663</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Biochem Cell Biol. 2008;40(1):14-21</RefSource>
                <PMID Version="1">17466566</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Clin Nutr Metab Care. 2008 May;11(3):222-6</RefSource>
                <PMID Version="1">18403916</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Nutr. 2008 May;138(5):867-72</RefSource>
                <PMID Version="1">18424593</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Amino Acids. 2008 Jun;35(1):147-55</RefSource>
                <PMID Version="1">17978888</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochimie. 2008 Nov-Dec;90(11-12):1716-21</RefSource>
                <PMID Version="1">18706471</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Trends Biochem Sci. 2008 Dec;33(12):565-8</RefSource>
                <PMID Version="1">18929489</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Endocrinol Metab. 2009 Apr;296(4):E592-602</RefSource>
                <PMID Version="1">18765678</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2009 Apr;37(6):e45</RefSource>
                <PMID Version="1">19237396</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7088-92</RefSource>
                <PMID Version="1">10359843</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Neuropathol. 2000 Feb;99(2):169-76</RefSource>
                <PMID Version="1">10672324</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>FASEB J. 2000 Dec;14(15):2601-10</RefSource>
                <PMID Version="1">11099479</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 2000 Dec;141(12):4436-41</RefSource>
                <PMID Version="1">11108252</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocr Rev. 2001 Feb;22(1):53-74</RefSource>
                <PMID Version="1">11159816</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 2001 Mar;21(6):2192-202</RefSource>
                <PMID Version="1">11238952</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell. 2001 Jun;7(6):1165-76</RefSource>
                <PMID Version="1">11430820</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Nutr. 2001 Oct;131(10):2732-40</RefSource>
                <PMID Version="1">11584097</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell. 2000 Nov;6(5):1099-108</RefSource>
                <PMID Version="1">11106749</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2002 May 24;277(21):19198-205</RefSource>
                <PMID Version="1">11877448</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Clin Nutr. 2002 Jul;76(1):128-40</RefSource>
                <PMID Version="1">12081826</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 2002 Oct;22(19):6681-8</RefSource>
                <PMID Version="1">12215525</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2002 Nov;110(10):1383-8</RefSource>
                <PMID Version="1">12438433</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2002 Nov;110(10):1539-48</RefSource>
                <PMID Version="1">12438451</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell. 2003 Mar;11(3):619-33</RefSource>
                <PMID Version="1">12667446</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Endocrinol Metab. 2003 May;284(5):E915-22</RefSource>
                <PMID Version="1">12527558</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuroendocrinology. 2004 Jan;79(1):26-33</RefSource>
                <PMID Version="1">14755131</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2004 Feb 13;279(7):5288-97</RefSource>
                <PMID Version="1">14630918</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Exp Cell Res. 2004 Mar 10;294(1):223-35</RefSource>
                <PMID Version="1">14980516</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Nutr Biochem. 2004 Aug;15(8):442-51</RefSource>
                <PMID Version="1">15302078</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2004 Aug 27;279(35):36553-61</RefSource>
                <PMID Version="1">15213227</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 2009 May;150(5):2080-6</RefSource>
                <PMID Version="1">19106217</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Mol Cell Biol. 2009 May;10(5):307-18</RefSource>
                <PMID Version="1">19339977</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Trends Endocrinol Metab. 2009 Nov;20(9):436-43</RefSource>
                <PMID Version="1">19800252</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Mol Cell Biol. 2004 Oct;5(10):827-35</RefSource>
                <PMID Version="1">15459663</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Neonat. 1965-1966;9(1):197-202</RefSource>
                <PMID Version="1">5872074</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Adv Enzymol Relat Areas Mol Biol. 1982;53:201-37</RefSource>
                <PMID Version="1">7036679</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1985 Aug 15;260(17):9843-7</RefSource>
                <PMID Version="1">4019497</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Nutr. 1986 Jan;116(1):36-46</RefSource>
                <PMID Version="1">3080558</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol. 1986 Jul;251(1 Pt 1):G103-10</RefSource>
                <PMID Version="1">3728668</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Endocrinol Metab. 1988 Dec;67(6):1186-9</RefSource>
                <PMID Version="1">2903866</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Diabetes Res. 1988 Dec;9(4):187-91</RefSource>
                <PMID Version="1">3073905</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatr Res. 1990 Sep;28(3):261-5</RefSource>
                <PMID Version="1">2235124</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 1992 Sep 1;80(5):1207-12</RefSource>
                <PMID Version="1">1515639</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Nutr. 1993 May;123(5):947-56</RefSource>
                <PMID Version="1">8487106</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 1993 Oct 8;75(1):59-72</RefSource>
                <PMID Version="1">8402901</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Dev. 1993 Dec;7(12B):2609-17</RefSource>
                <PMID Version="1">8276243</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Chromatogr. 1993 Oct 22;620(1):143-8</RefSource>
                <PMID Version="1">8106581</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drugs. 1995 Oct;50(4):595-601</RefSource>
                <PMID Version="1">8536548</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol. 1997 Jun;272(6 Pt 1):G1382-90</RefSource>
                <PMID Version="1">9227473</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatr Res. 1998 Apr;43(4 Pt 1):442-51</RefSource>
                <PMID Version="1">9544996</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1998 Jun 5;273(23):14484-94</RefSource>
                <PMID Version="1">9603962</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000592">Amino Acid Metabolism, Inborn Errors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000833">Animals, Suckling</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001119">Arginase</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001120">Arginine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000172">deficiency</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001402">B-Lymphocytes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013006">Growth Hormone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006201">Hair Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007003">Hypoglycemia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007334">Insulin-Like Growth Factor I</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D046912">Multiprotein Complexes</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009135">Muscular Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017346">Protein-Serine-Threonine Kinases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011506">Proteins</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D015398">Signal Transduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013577">Syndrome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D058570">TOR Serine-Threonine Kinases</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC3058991</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2011</Year>
                <Month>1</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>1</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>1</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>5</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">M110.216119</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.M110.216119</ArticleId>
            <ArticleId IdType="pubmed">21239484</ArticleId>
            <ArticleId IdType="pmc">PMC3058991</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2505629</PMID>
        <DateCreated>
            <Year>1989</Year>
            <Month>09</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1989</Year>
            <Month>09</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-2409</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>44</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>1989</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anaesthesia</Title>
                <ISOAbbreviation>Anaesthesia</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sinus arrest after alfentanil and suxamethonium.</ArticleTitle>
            <Pagination>
                <MedlinePgn>614</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ananthanarayan</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Anaesthesia</MedlineTA>
            <NlmUniqueID>0370524</NlmUniqueID>
            <ISSNLinking>0003-2409</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000777">Anesthetics</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1N74HM2BS7</RegistryNumber>
                <NameOfSubstance UI="D015760">Alfentanil</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>J2R869A8YF</RegistryNumber>
                <NameOfSubstance UI="D013390">Succinylcholine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>UF599785JZ</RegistryNumber>
                <NameOfSubstance UI="D005283">Fentanyl</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015760">Alfentanil</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000771">Anesthesia, Intravenous</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000777">Anesthetics</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005283">Fentanyl</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006323">Heart Arrest</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013390">Succinylcholine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1989</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1989</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1989</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2505629</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12775141</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>05</Month>
            <Day>30</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>06</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1081-1206</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>90</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of allergy, asthma &amp; immunology : official publication of the American College of Allergy, Asthma, &amp; Immunology</Title>
                <ISOAbbreviation>Ann. Allergy Asthma Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Drug-induced rash with eosinophilia and systemic symptoms syndrome with bupropion administration.</ArticleTitle>
            <Pagination>
                <MedlinePgn>572-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sustained-release bupropion is commonly used for the symptomatic relief of depressive illness and as an adjuvant in smoking cessation therapy.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To report a case of bupropion-induced drug rash with eosinophilia and systemic symptoms syndrome, including acute hepatitis, obstructive lung disease, and myositis.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">After the patient discontinued use of bupropion, serologic tests, muscle biopsies, pulmonary function tests, a chest x-ray examination, venous Doppler ultrasounds, and an electrocardiogram were performed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">On discontinuation of bupropion and prolonged systemic corticosteroid therapy, there was complete resolution of symptoms.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">To our knowledge, this is the first reported case of drug rash with eosinophilia and systemic symptoms syndrome induced by bupropion therapy. We report this case to notify clinicians of the potential serious multisystem complications that can occur with sustained-release bupropion therapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bagshaw</LastName>
                    <ForeName>Sean M</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cload</LastName>
                    <ForeName>Bruce</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gilmour</LastName>
                    <ForeName>Janet</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leung</LastName>
                    <ForeName>Stephen T</ForeName>
                    <Initials>ST</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bowen</LastName>
                    <ForeName>Thomas J</ForeName>
                    <Initials>TJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Ann Allergy Asthma Immunol</MedlineTA>
            <NlmUniqueID>9503580</NlmUniqueID>
            <ISSNLinking>1081-1206</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>01ZG3TPX31</RegistryNumber>
                <NameOfSubstance UI="D016642">Bupropion</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9PHQ9Y1OLM</RegistryNumber>
                <NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018687">Antidepressive Agents, Second-Generation</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016642">Bupropion</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D002170">Canada</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004802">Eosinophilia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005076">Exanthema</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006505">Hepatitis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008173">Lung Diseases, Obstructive</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009220">Myositis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D010679">Philippines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000208">ethnology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011239">Prednisolone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016540">Smoking Cessation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013577">Syndrome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>5</Month>
                <Day>31</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>6</Month>
                <Day>20</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>5</Month>
                <Day>31</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12775141</ArticleId>
            <ArticleId IdType="pii">S1081-1206(10)61853-4</ArticleId>
            <ArticleId IdType="doi">10.1016/S1081-1206(10)61853-4</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12236580</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>09</Month>
            <Day>18</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>04</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0300-8177</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>237</Volume>
                    <Issue>1-2</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular and cellular biochemistry</Title>
                <ISOAbbreviation>Mol. Cell. Biochem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Antihypertensive and metabolic effects of whole Maitake mushroom powder and its fractions in two rat strains.</ArticleTitle>
            <Pagination>
                <MedlinePgn>129-36</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Maitake mushroom has been reported to favorably influence hypertension and diabetes mellitus. The purpose of this study was to compare the effects of whole Maitake mushroom powder and two extracts designated as ether soluble (ES) and water soluble (WS) on Zucker fatty rats (ZFR), a model of insulin resistance, and on spontaneously hypertensive rats (SHR), a model of genetic hypertension. In the initial study, we followed four groups of eight ZFR and SHR receiving special diets: a baseline diet (BD), BD + whole Maitake mushroom powder (20% w/w), BD + fraction ES (0.10% w/w), and BD + WS (0.22% w/w). Different effects of these dietary regimens on the 2 rat strains were found. At 35 days, only consumption of the ES diet significantly decreased systolic BP (SBP) in SHR (average 197 vs. 176 mm Hg, p &lt; 0.001), while in ZFR only the groups consuming the whole Maitake and WS diets showed significantly decreased SBP (138 vs. 120-125 mm Hg, p &lt; 0.001). A challenge test with losartan (an angiotensin II receptor blocker) indicates that angiotensin II does not play a major role in SBP regulation of ZFR, but does in SHR where consumption of ES relative to other groups significantly lowered activity of this system. In SHR, glucose, cholesterol, circulating insulin and HbA1C were virtually similar among all dietary groups; but whole Maitake (-22%), ES (-120%) and WS (-80%) diets were associated with decreased triglycerides, and the ES diet with lowered serum creatinine (-29%). In ZFR, circulating insulin and HbA1C were significantly decreased in the whole Maitake powder and ES groups, and tended to be lower in the WS group compared to control. In the ensuing studies, we gavaged ZFR once daily with water (control), 44 mg fraction WS, or 44 mg fraction WS plus 100 microg niacin-bound chromium (NBC). Oral gavage of WS clearly lowered SBP and circulating glucose concentrations, more so with the addition of chromium. We conclude that the examined forms of Maitake mushroom have antihypertensive and antidiabetic potential which differ among rat strains. The ES fraction may decrease SBP in SHR via alteration in the renin-angiotensin system.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Talpur</LastName>
                    <ForeName>Nadeem A</ForeName>
                    <Initials>NA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Physiology and Biophysics, Georgetown University Medical Center, Washington, DC 20007, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Echard</LastName>
                    <ForeName>Bobby W</ForeName>
                    <Initials>BW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fan</LastName>
                    <ForeName>Arthur Yin</ForeName>
                    <Initials>AY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jaffari</LastName>
                    <ForeName>Omeed</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bagchi</LastName>
                    <ForeName>Debasis</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Preuss</LastName>
                    <ForeName>Harry G</ForeName>
                    <Initials>HG</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Mol Cell Biochem</MedlineTA>
            <NlmUniqueID>0364456</NlmUniqueID>
            <ISSNLinking>0300-8177</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017392">Thiobarbituric Acid Reactive Substances</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>97C5T2UQ7J</RegistryNumber>
                <NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>AYI8EX34EU</RegistryNumber>
                <NameOfSubstance UI="D003404">Creatinine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>IY9XDZ35W2</RegistryNumber>
                <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>JMS50MPO89</RegistryNumber>
                <NameOfSubstance UI="D019808">Losartan</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000363">Agaricales</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000959">Antihypertensive Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001786">Blood Glucose</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001835">Body Weight</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002784">Cholesterol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003404">Creatinine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007328">Insulin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015227">Lipid Peroxidation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019808">Losartan</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010936">Plant Extracts</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011918">Rats, Inbred SHR</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011924">Rats, Zucker</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013045">Species Specificity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017392">Thiobarbituric Acid Reactive Substances</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>9</Month>
                <Day>19</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>4</Month>
                <Day>16</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>9</Month>
                <Day>19</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12236580</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15792986</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>07</Month>
            <Day>14</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>09</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0363-6135</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>289</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Heart and circulatory physiology</Title>
                <ISOAbbreviation>Am. J. Physiol. Heart Circ. Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Moderate endurance training prevents doxorubicin-induced in vivo mitochondriopathy and reduces the development of cardiac apoptosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>H722-31</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The objective of this work was to test the hypothesis that endurance training may be protective against in vivo doxorubicin (DOX)-induced cardiomyopathy through mitochondria-mediated mechanisms. Forty adult (6-8 wk old) male Wistar rats were randomly divided into four groups (n = 10/group): nontrained, nontrained + DOX treatment (20 mg/kg), trained (14 wk of endurance treadmill running, 60-90 min/day), and trained + DOX treatment. Mitochondrial respiration, calcium tolerance, oxidative damage, heat shock proteins (HSPs), antioxidant enzyme activity, and apoptosis markers were evaluated. DOX induces mitochondrial respiratory dysfunction, oxidative damage, and histopathological lesions and triggers apoptosis (P &lt; 0.05, n = 10). However, training limited the decrease in state 3 respiration, respiratory control ratio (RCR), uncoupled respiration, aconitase activity, and protein sulfhydryl content caused by DOX treatment and prevented the increased sensitivity to calcium in nontrained + DOX-treated rats (P &lt; 0.05, n = 10). Moreover, training inhibited the DOX-induced increase in mitochondrial protein carbonyl groups, malondialdehyde, Bax, Bax-to-Bcl-2 ratio, and tissue caspase-3 activity (P &lt; 0.05, n = 10). Training also increased by approximately 2-fold the expression of mitochondrial HSP-60 and tissue HSP-70 (P &lt; 0.05, n = 10) and by approximately 1.5-fold the activity of mitochondrial and cytosolic forms of SOD (P &lt; 0.05, n = 10). We conclude that endurance training protects heart mitochondrial respiratory function from the toxic effects of DOX, probably by improving mitochondrial and cell defense systems and reducing cell oxidative stress. In addition, endurance training limited the DOX-triggered apoptosis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ascenso</LastName>
                    <ForeName>Antnio</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Sport Biology, Faculty of Sport Sciences, Univ. of Porto, Rua Dr. Plcido Costa, 91, 4200-450 Porto, Portugal. aascensao@fcdef.up.pt</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Magalhes</LastName>
                    <ForeName>Jos</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Soares</LastName>
                    <ForeName>Jos M C</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferreira</LastName>
                    <ForeName>Rita</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neuparth</LastName>
                    <ForeName>Maria J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marques</LastName>
                    <ForeName>Franklim</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oliveira</LastName>
                    <ForeName>Paulo J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Duarte</LastName>
                    <ForeName>Jos A</ForeName>
                    <Initials>JA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2005</Year>
                <Month>03</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Physiol Heart Circ Physiol</MedlineTA>
            <NlmUniqueID>100901228</NlmUniqueID>
            <ISSNLinking>0363-6135</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>80168379AG</RegistryNumber>
                <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009202">Cardiomyopathies</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006321">Heart</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008929">Mitochondria, Heart</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D028361">Mitochondrial Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018384">Oxidative Stress</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010101">Oxygen Consumption</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D010805">Physical Conditioning, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D010807">Physical Endurance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>9</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">01249.2004</ArticleId>
            <ArticleId IdType="doi">10.1152/ajpheart.01249.2004</ArticleId>
            <ArticleId IdType="pubmed">15792986</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9353414</PMID>
        <DateCreated>
            <Year>1997</Year>
            <Month>12</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1997</Year>
            <Month>12</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0022-3565</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>283</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>1997</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of pharmacology and experimental therapeutics</Title>
                <ISOAbbreviation>J. Pharmacol. Exp. Ther.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid.</ArticleTitle>
            <Pagination>
                <MedlinePgn>918-24</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Dexanabinol, HU-211, a synthetic cannabinoid devoid of psychotropic effects, improves neurological outcome in models of brain trauma, ischemia and meningitis. Recently, HU-211 was found to inhibit brain tumor necrosis factor (TNFalpha) production after head injury. In the present study, we demonstrate the ability of HU-211 to suppress TNFalpha production and to rescue mice and rats from endotoxic shock after LPS (Escherichia coli 055:B5) inoculation. In BALB/c mice, a dose of 10 mg/kg LPS, injected i.p., caused 57% and 100% mortality, at 24 and 48 hr, respectively. HU-211, administered i.p. 30 min before lipopolysaccharide (LPS), reduced lethality to 9 and 67% at these time points (P &lt; .05). When coinjected with D-galactoseamine (i.p.), LPS was 100% lethal within 24 hr, whereas eight hourly injections of HU-211 caused mortality of C57BL/6 mice to drop to 10% (P &lt; .001). Administration of LPS to Sprague-Dawley rats resulted in a 30% reduction in the mean arterial blood pressure within 30 min, which persisted for 3 hr. HU-211, given 2 to 3 min before LPS, completely abolished the typical hypotensive response. Furthermore, the drug also markedly suppressed in vitro TNFalpha production and nitric oxide generation (by &gt;90%) by both murine peritoneal macrophages and rat alveolar macrophage cell line exposed to LPS. HU-211 may, therefore, have therapeutic implications in the treatment of TNFalpha-mediated pathologies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gallily</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Immunology, The Hebrew University, Faculty of Medicine, Jerusalem, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamin</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Waksmann</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ovadia</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weidenfeld</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bar-Joseph</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Biegon</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mechoulam</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shohami</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Pharmacol Exp Ther</MedlineTA>
            <NlmUniqueID>0376362</NlmUniqueID>
            <ISSNLinking>0022-3565</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>112924-45-5</RegistryNumber>
                <NameOfSubstance UI="C062018">HU 211</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>31C4KY9ESH</RegistryNumber>
                <NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7J8897W37S</RegistryNumber>
                <NameOfSubstance UI="D013759">Dronabinol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>W980KJ009P</RegistryNumber>
                <NameOfSubstance UI="D003345">Corticosterone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003345">Corticosterone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013759">Dronabinol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008070">Lipopolysaccharides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008264">Macrophages</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009569">Nitric Oxide</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012772">Shock, Septic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000096">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1997</Year>
                <Month>11</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1997</Year>
                <Month>11</Month>
                <Day>14</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1997</Year>
                <Month>11</Month>
                <Day>14</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9353414</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16684804</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>08</Month>
            <Day>17</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>10</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1531-2267</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>26</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Aug</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Physiological genomics</Title>
                <ISOAbbreviation>Physiol. Genomics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Diabetes-altered gene expression in rat skeletal muscle corrected by oral administration of vanadyl sulfate.</ArticleTitle>
            <Pagination>
                <MedlinePgn>192-201</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Treatment with vanadium, a representative of a class of antidiabetic compounds, alleviates diabetic hyperglycemia and hyperlipidemia. Oral administration of vanadium compounds in animal models and humans does not cause clinical symptoms of hypoglycemia, a common problem for diabetic patients with insulin treatment. Gene expression, using Affymetrix arrays, was examined in muscle from streptozotocin-induced diabetic and normal rats in the presence or absence of oral vanadyl sulfate treatment. This treatment affected normal rats differently from diabetic rats, as demonstrated by two-way ANOVA of the full array data. Diabetes altered the expression of 133 genes, and the expression of 30% of these genes dysregulated in diabetes was normalized by vanadyl sulfate treatment. For those genes, the ratio of expression in normal animals to the expression in diabetic animals showed a strong negative correlation with the ratio of expression in diabetic animals to the expression in diabetic animals treated with vanadyl sulfate (P = -0.85). The genes identified belong to six major metabolic functional groups: lipid metabolism, oxidative stress, muscle structure, protein breakdown and biosynthesis, the complement system, and signal transduction. The identification of oxidative stress genes, coupled with the known oxidative chemistry of vanadium, implicates reactive oxygen species in the action of this class of compounds. These results imply that early transition metals or compounds formed from their chemical interactions with other metabolites may act as general transcription modulators, a role not usually associated with this class of compounds.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Willsky</LastName>
                    <ForeName>Gail R</ForeName>
                    <Initials>GR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, School of Medicine and Biomedical Sciences, The State University of New York (SUNY) at Buffalo, Buffalo, New York 14214, USA. gwillsky@buffalo.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chi</LastName>
                    <ForeName>Lai-Har</ForeName>
                    <Initials>LH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liang</LastName>
                    <ForeName>Yulan</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gaile</LastName>
                    <ForeName>Daniel P</ForeName>
                    <Initials>DP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Zihua</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Crans</LastName>
                    <ForeName>Debbie C</ForeName>
                    <Initials>DC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>GM-40525</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2006</Year>
                <Month>05</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Physiol Genomics</MedlineTA>
            <NlmUniqueID>9815683</NlmUniqueID>
            <ISSNLinking>1094-8341</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005230">Fatty Acids, Nonesterified</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017968">Vanadium Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6DU9Y533FA</RegistryNumber>
                <NameOfSubstance UI="C034028">vanadyl sulfate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>97C5T2UQ7J</RegistryNumber>
                <NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000704">Analysis of Variance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001786">Blood Glucose</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002784">Cholesterol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003921">Diabetes Mellitus, Experimental</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005230">Fatty Acids, Nonesterified</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006943">Hyperglycemia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007004">Hypoglycemic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050356">Lipid Metabolism</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018482">Muscle, Skeletal</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020411">Oligonucleotide Array Sequence Analysis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018384">Oxidative Stress</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014280">Triglycerides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017968">Vanadium Compounds</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2006</Year>
                <Month>5</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>5</Month>
                <Day>11</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>10</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>5</Month>
                <Day>11</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">00196.2005</ArticleId>
            <ArticleId IdType="doi">10.1152/physiolgenomics.00196.2005</ArticleId>
            <ArticleId IdType="pubmed">16684804</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17033500</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>10</Month>
            <Day>11</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>01</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>08</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1076-2752</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>48</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of occupational and environmental medicine / American College of Occupational and Environmental Medicine</Title>
                <ISOAbbreviation>J. Occup. Environ. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Depression and pesticide exposures in female spouses of licensed pesticide applicators in the agricultural health study cohort.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1005-13</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This nested case-control study evaluated the association between depression and pesticide exposure among women.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The study population included 29,074 female spouses of private pesticide applicators enrolled in the Agricultural Health Study between 1993 and 1997. Cases were women who had physician-diagnosed depression requiring medication. Lifetime pesticide use was categorized as never mixed/applied pesticides, low exposure (up to 225 days), high exposure (&gt;225 days), and a history of diagnosed pesticide poisoning.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">After adjustment for state, age, race, off-farm work, alcohol, cigarette smoking, physician visits, and solvent exposure, depression was significantly associated with a history of pesticide poisoning (odds ratio [OR] = 3.26; 95% confidence interval [CI] = 1.72-6.19) but not low (OR = 1.09; CI = 0.91-1.31) or high (OR = 1.09; 95% CI = 0.91-1.31) cumulative pesticide exposure.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Pesticide poisoning may contribute to risk of depression.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Beseler</LastName>
                    <ForeName>Cheryl</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Colorado Injury Control Research Center, Department of Psychology, Colorado State University, Fort Collins, Colorado 80523, USA. cbeseler@lamar,colostate.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stallones</LastName>
                    <ForeName>Lorann</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hoppin</LastName>
                    <ForeName>Jane A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alavanja</LastName>
                    <ForeName>Michael C R</ForeName>
                    <Initials>MC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blair</LastName>
                    <ForeName>Aaron</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Keefe</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kamel</LastName>
                    <ForeName>Freya</ForeName>
                    <Initials>F</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>Z01 ES044007-05</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Occup Environ Med</MedlineTA>
            <NlmUniqueID>9504688</NlmUniqueID>
            <ISSNLinking>1076-2752</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016573">Agrochemicals</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010575">Pesticides</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Lab Clin Med. 2000 Sep;136(3):168-80</RefSource>
                <PMID Version="1">10985495</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Lett. 2001 Mar 31;120(1-3):343-51</RefSource>
                <PMID Version="1">11323193</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Community Health. 2002 Jun;27(3):213-28</RefSource>
                <PMID Version="1">12027271</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Epidemiol. 2002 Aug;12(6):389-94</RefSource>
                <PMID Version="1">12160597</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Occup Environ Med. 2003 Apr;60(4):279-86</RefSource>
                <PMID Version="1">12660376</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 2003 Apr;72(2):267-71</RefSource>
                <PMID Version="1">12660361</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7983-7</RefSource>
                <PMID Version="1">12805562</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Inj Prev. 2003 Sep;9(3):241-4</RefSource>
                <PMID Version="1">12966013</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Soc Psychiatry. 2000 Spring;46(1):67-73</RefSource>
                <PMID Version="1">14529080</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Occup Environ Med. 2004 Mar;61(3):201-11</RefSource>
                <PMID Version="1">14985514</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2004 May 1;196(3):319-26</RefSource>
                <PMID Version="1">15094302</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2004 Jun 4;279(23):24024-33</RefSource>
                <PMID Version="1">15044461</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2004 Jun;112(9):950-8</RefSource>
                <PMID Version="1">15198914</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Occup Environ Med. 2004 Aug;46(8):856-65</RefSource>
                <PMID Version="1">15300138</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Environ Health. 1975 Feb;30(2):98-103</RefSource>
                <PMID Version="1">1115534</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 1983 May;23(3):717-23</RefSource>
                <PMID Version="1">6865914</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fundam Appl Toxicol. 1981 Mar-Apr;1(2):154-60</RefSource>
                <PMID Version="1">6192030</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Ind Med. 1987;12(2):153-72</RefSource>
                <PMID Version="1">3661569</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Environ Health. 1988 Jan-Feb;43(1):38-45</RefSource>
                <PMID Version="1">3355242</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Intern Med. 1990 May;150(5):1083-8</RefSource>
                <PMID Version="1">2184790</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 2000 Sep;58(3):577-83</RefSource>
                <PMID Version="1">10953051</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2000 Apr;108(4):293-300</RefSource>
                <PMID Version="1">10753086</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Fam Pract. 1999 Dec;48(12):965-72</RefSource>
                <PMID Version="1">10628577</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Phys Med Rehabil. 1991 Jun;72(7):460-4</RefSource>
                <PMID Version="1">2059116</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Agric Saf Health. 2005 May;11(2):141-50</RefSource>
                <PMID Version="1">15931940</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Expo Anal Environ Epidemiol. 2005 May;15(3):225-33</RefSource>
                <PMID Version="1">15280893</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Aerosp Med. 1964 May;35:474-8</RefSource>
                <PMID Version="1">14170934</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am Fam Physician. 1999 Jul;60(1):225-34, 239-40</RefSource>
                <PMID Version="1">10414640</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochim Biophys Acta. 1999 Jul 9;1439(1):1-16</RefSource>
                <PMID Version="1">10395961</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Psychiatry. 1997;58 Suppl 15:12-8</RefSource>
                <PMID Version="1">9427872</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Ind Med. 1997 Nov;32(5):487-96</RefSource>
                <PMID Version="1">9327072</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Res. 1997;73(1-2):193-9</RefSource>
                <PMID Version="1">9311547</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 1991 Jul 27;338(8761):223-7</RefSource>
                <PMID Version="1">1676786</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Res. 1992 Oct;59(1):217-28</RefSource>
                <PMID Version="1">1425511</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Occup Med. 1993 Oct-Dec;8(4):869-82</RefSource>
                <PMID Version="1">8303498</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Public Health. 1994 May;84(5):731-6</RefSource>
                <PMID Version="1">8179040</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Fam Med. 1995 Feb;4(2):99-105</RefSource>
                <PMID Version="1">7842160</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 1995 May 6;345(8958):1135-9</RefSource>
                <PMID Version="1">7723544</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gen Hosp Psychiatry. 1995 Jan;17(1):3-12</RefSource>
                <PMID Version="1">7737492</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Environ Health. 1995 Nov-Dec;50(6):440-4</RefSource>
                <PMID Version="1">8572722</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychopharmacol Bull. 1995;31(4):711-8</RefSource>
                <PMID Version="1">8851644</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fundam Appl Toxicol. 1997 Aug;38(2):148-57</RefSource>
                <PMID Version="1">9299188</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000382">Agricultural Workers' Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016573">Agrochemicals</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003863">Depression</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004781">Environmental Exposure</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006306">Health Surveys</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007484">Iowa</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D009657">North Carolina</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016017">Odds Ratio</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010575">Pesticides</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D018454">Spouses</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS11731</OtherID>
        <OtherID Source="NLM">PMC1626656</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>10</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>1</Month>
                <Day>5</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>10</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.jom.0000235938.70212.dd</ArticleId>
            <ArticleId IdType="pii">00043764-200610000-00009</ArticleId>
            <ArticleId IdType="pubmed">17033500</ArticleId>
            <ArticleId IdType="pmc">PMC1626656</ArticleId>
            <ArticleId IdType="mid">NIHMS11731</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2157151</PMID>
        <DateCreated>
            <Year>1990</Year>
            <Month>05</Month>
            <Day>03</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1990</Year>
            <Month>05</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0148-639X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>13</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1990</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Muscle &amp; nerve</Title>
                <ISOAbbreviation>Muscle Nerve</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Polyneuropathy in lithium intoxication.</ArticleTitle>
            <Pagination>
                <MedlinePgn>204-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Two patients developed acute sensorimotor polyneuropathy after intoxication with lithium carbonate. Nerve conduction studies, electromyography, and sural nerve biopsy proved it to be an axonal neuropathy. Recovery of muscle strength, reflexes, and sensory function started weeks after discontinuation of lithium therapy. One patient fully recovered within a year. In the literature we found nine other cases of lithium polyneuropathy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Vanhooren</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>UZ Gasthuisberg, Department of Neurology, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dehaene</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van Zandycke</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Piessens</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vandenbergh</LastName>
                    <ForeName>V</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van Hees</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lammens</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carton</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Muscle Nerve</MedlineTA>
            <NlmUniqueID>7803146</NlmUniqueID>
            <ISSNLinking>0148-639X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>2BMD2GNA4V</RegistryNumber>
                <NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9FN79X2M3F</RegistryNumber>
                <NameOfSubstance UI="D008094">Lithium</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Muscle Nerve. 1991 Jun;14(6):578</RefSource>
                <PMID Version="1">1649400</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004576">Electromyography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008094">Lithium</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000506">poisoning</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016651">Lithium Carbonate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009431">Neural Conduction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010523">Peripheral Nervous System Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1990</Year>
                <Month>3</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1990</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1990</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2157151</ArticleId>
            <ArticleId IdType="doi">10.1002/mus.880130306</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16189749</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>09</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>01</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0176-3679</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>38</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacopsychiatry</Title>
                <ISOAbbreviation>Pharmacopsychiatry</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Necrotizing enterocolitis after antipsychotic treatment involving clozapine and review of severe digestive complications -- a case report.</ArticleTitle>
            <Pagination>
                <MedlinePgn>220-1</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A case of necrotizing enterocolitis in a 19-year old man treated for schizophrenic disorder, induced by a drug association involving clozapine and requiring surgical treatment, is presented. To our knowledge only few reports have described the occurrence of this complication with atypical antipsychotics. Evidence for linking this complication to clozapine was reinforced by the absence of any viral or bacterial infection. The authors present a review of similar cases, stress the potential hazards induced by such drug combinations and discuss supposed mechanisms of this enterocolitis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Khaldi</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gourevitch</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matmar</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Llory</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oli</LastName>
                    <ForeName>J-P</ForeName>
                    <Initials>JP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chauvelot-Moachon</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Pharmacopsychiatry</MedlineTA>
            <NlmUniqueID>8402938</NlmUniqueID>
            <ISSNLinking>0176-3679</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.3.2</RegistryNumber>
                <NameOfSubstance UI="D003402">Creatine Kinase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>J60AR2IKIC</RegistryNumber>
                <NameOfSubstance UI="D003024">Clozapine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000900">Anti-Bacterial Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003024">Clozapine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003402">Creatine Kinase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020345">Enterocolitis, Necrotizing</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012559">Schizophrenia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>19</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>9</Month>
                <Day>29</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>1</Month>
                <Day>21</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>9</Month>
                <Day>29</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-2005-873157</ArticleId>
            <ArticleId IdType="pubmed">16189749</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9823552</PMID>
        <DateCreated>
            <Year>1998</Year>
            <Month>12</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1998</Year>
            <Month>12</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0399-8320</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>22</Volume>
                    <Issue>8-9</Issue>
                    <PubDate>
                        <MedlineDate>1998 Aug-Sep</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Gastroentrologie clinique et biologique</Title>
                <ISOAbbreviation>Gastroenterol. Clin. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Nephropathy and 5-aminosalicylic acid].</ArticleTitle>
            <Pagination>
                <MedlinePgn>663-4</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bonnet</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>fre</Language>
            <PublicationTypeList>
                <PublicationType UI="D016421">Editorial</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Nphropathie et acide 5-aminosalicylique.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>FRANCE</Country>
            <MedlineTA>Gastroenterol Clin Biol</MedlineTA>
            <NlmUniqueID>7704825</NlmUniqueID>
            <ISSNLinking>0399-8320</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4Q81I59GXC</RegistryNumber>
                <NameOfSubstance UI="D019804">Mesalamine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007668">Kidney</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007674">Kidney Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019804">Mesalamine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1998</Year>
                <Month>11</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1998</Year>
                <Month>11</Month>
                <Day>21</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1998</Year>
                <Month>11</Month>
                <Day>21</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9823552</ArticleId>
            <ArticleId IdType="pii">MDOI-GCB-10-1998-22-8-9-0399-8320-101019-ART52</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12765889</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>05</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>06</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0007-0912</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>90</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of anaesthesia</Title>
                <ISOAbbreviation>Br J Anaesth</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sedation caused by clonidine in patients with spinal cord injury.</ArticleTitle>
            <Pagination>
                <MedlinePgn>742-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In patients with spinal cord injury, cephalad spread of intrathecal (i.t.) medication could be delayed.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We used bispectral index and an observer scale to assess sedation after two different doses of i.t. clonidine in patients with or without spinal cord injury. Twelve patients with neurological deficit caused by trauma (Spinal Cord Injury, SCI) were compared with patients without neurological disease. They received 10 mg of i.t. bupivacaine with clonidine, with either 50 microg (low dose, n=6) or 150 microg (high dose, n=6) at L(2)-L(3). A further 12 patients, six with spinal trauma lesion and six healthy, received i.t. bupivacaine and 150 micro g of i.m. clonidine.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Sedation and a decrease in BIS occurred only in patients receiving 150 microg of clonidine. Onset of sedation and the decrease in BIS was delayed in most spinal cord injured patients whatever the route of administration (P&lt;0.001). Duration of sedation was not different between the groups. Delayed sedation and decrease of BIS after i.t. clonidine in patients with spinal cord injury are similar than those observed after i.m. clonidine.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A systemic effect is likely to be the main reason for sedation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Malinovsky</LastName>
                    <ForeName>J-M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Anaesthesia and Intensive Care, Htel-Dieu, 44093 Nantes Cedex 1, France. jeanmarc.malinovsky@chu-nantes.fr</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malinge</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lepage</LastName>
                    <ForeName>J-Y</ForeName>
                    <Initials>JY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pinaud</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Br J Anaesth</MedlineTA>
            <NlmUniqueID>0372541</NlmUniqueID>
            <ISSNLinking>0007-0912</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000316">Adrenergic alpha-Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000700">Analgesics</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>MN3L5RMN02</RegistryNumber>
                <NameOfSubstance UI="D003000">Clonidine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000316">Adrenergic alpha-Agonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000700">Analgesics</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000704">Analysis of Variance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003000">Clonidine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016292">Conscious Sedation</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004569">Electroencephalography</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007273">Injections, Intramuscular</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007278">Injections, Spinal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013119">Spinal Cord Injuries</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018709">Statistics, Nonparametric</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>5</Month>
                <Day>27</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>6</Month>
                <Day>27</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>5</Month>
                <Day>27</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12765889</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17767966</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>09</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>12</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0166-445X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>85</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Nov</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Aquatic toxicology (Amsterdam, Netherlands)</Title>
                <ISOAbbreviation>Aquat. Toxicol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Comparisons of tissue-specific transcription of stress response genes with whole animal endpoints of adverse effect in striped bass (Morone saxatilis) following treatment with copper and esfenvalerate.</ArticleTitle>
            <Pagination>
                <MedlinePgn>28-39</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Changes in the gene transcription of stress response genes in resident fish can be powerful biomarkers for the identification of sublethal impacts of environmental stressors on aquatic ecosystems. In this study, we tested the effects of two reference toxicants, copper (Cu) and the pyrethroid insecticide esfenvalerate [(S)-alpha-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl)-3-methylbutyrate], on lethal (mortality) and sublethal endpoints (growth, swimming behavior, transcription levels of stress response genes) in juvenile (81-90-day-old) striped bass (Morone saxatilis). We established cellular stress response markers for proteotoxicity (HSP70, HSP90), phase I detoxification mechanism (CYP1A1), metal-binding (metallothionein), as well as immune-function and pathogen-defense (TGF-beta, Mx-protein, nRAMP). Quantitative real-time TaqMan PCR was used to examine tissue-specific changes in the transcriptome of liver, spleen, white muscle, anterior kidney and gills after 7-day Cu exposures and 24-h esfenvalerate exposures. On the transcriptome level, exposure to Cu showed strongest effects on the transcription of metallothionein in spleen tissue, causing a 4-fold increase of mRNA at 42ppb total Cu and a 10-fold increase at 160 ppb Cu. Exposure to Cu also caused significant tissue-specific changes in gene transcription for immune-system related genes. Esfenvalerate exposure had tissue-specific effects on the transcription of HSP70, HSP90 and CYP1A1. The most significant effects were detected in liver tissue after exposure to 0.64 microg/L esfenvalerate. Our results show that the stress response at the transcriptome level is a more sensitive indicator for Cu and esfenvalerate exposures at low concentrations than swimming behavior, growth or mortality. The accuracy of studies on quantitative changes in the transcriptome can benefit from an initial evaluation or the inclusion of several different tissues and the use of multiple housekeeping genes.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Geist</LastName>
                    <ForeName>Juergen</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fish Biology Unit, Department of Animal Science, Technische Universitt Mnchen, D-85350, Freising, Germany. geist@wzw.tum.de</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Werner</LastName>
                    <ForeName>Inge</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eder</LastName>
                    <ForeName>Kai J</ForeName>
                    <Initials>KJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leutenegger</LastName>
                    <ForeName>Christian M</ForeName>
                    <Initials>CM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2007</Year>
                <Month>07</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Aquat Toxicol</MedlineTA>
            <NlmUniqueID>8500246</NlmUniqueID>
            <ISSNLinking>0166-445X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D029941">Fish Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007306">Insecticides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009570">Nitriles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011722">Pyrethrins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014874">Water Pollutants, Chemical</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>789U1901C5</RegistryNumber>
                <NameOfSubstance UI="D003300">Copper</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Z6MXZ39302</RegistryNumber>
                <NameOfSubstance UI="C017690">fenvalerate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001492">Bass</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003300">Copper</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017931">DNA Primers</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D029941">Fish Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000662">veterinary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007306">Insecticides</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009570">Nitriles</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011722">Pyrethrins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000662">veterinary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013312">Stress, Physiological</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000662">veterinary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016019">Survival Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014874">Water Pollutants, Chemical</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2007</Year>
                <Month>4</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2007</Year>
                <Month>7</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2007</Year>
                <Month>7</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2007</Year>
                <Month>7</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>9</Month>
                <Day>5</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>12</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>9</Month>
                <Day>5</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0166-445X(07)00294-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.aquatox.2007.07.011</ArticleId>
            <ArticleId IdType="pubmed">17767966</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
